COMMUNIQUÉS West-GlobeNewswire

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
28/04/2025
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN [...]
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
28/04/2025
- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in combination with [...]
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
28/04/2025
Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support [...]
LifeMD Acquires Women’s Health Provider Optimal Human Health MD to Accelerate Entry into the Women’s Health Market
28/04/2025
Acquisition Establishes Clinical and Operational Foundation for LifeMD’s Comprehensive Women’s Health Offering, Launching Summer 2025 NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading [...]
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
28/04/2025
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
28/04/2025
First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine [...]
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
28/04/2025
New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. ( [...]
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
28/04/2025
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today [...]
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
28/04/2025
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug [...]
EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease
28/04/2025
Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD and faricimab on [...]
Widmer Brothers Brewing Celebrates 40th Anniversary
28/04/2025
Portland Brewery Marks Four Decades of Widmer Beer with ‘40 Years of Cheers’ and Re-release of Four Iconic Brews PORTLAND, Ore., April 28, 2025 (GLOBE NEWSWIRE) -- Widmer Brothers Brewing , the creator of the Original [...]
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
28/04/2025
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 [...]
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
28/04/2025
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare [...]
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
28/04/2025
MILAN, April 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, [...]
Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
28/04/2025
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best [...]
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
28/04/2025
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s [...]
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
28/04/2025
ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to [...]
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
28/04/2025
Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both adaptive and innate anti [...]
Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
28/04/2025
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics , a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today [...]

Pages